Literature DB >> 31260800

Coping and Modifiable Psychosocial Factors are Associated with Mood and Quality of Life in Patients with Chronic Graft-versus-Host Disease.

Jamie M Jacobs1, Sarah Fishman2, Robert Sommer2, Isabella Sereno2, Alyssa Fenech2, Amanda L Jankowski2, Lara Traeger3, Joseph A Greer3, Julie Vanderklish4, Chrisa Hunnewell4, Meredith Saylor4, Yi-Bin Chen5, Thomas Spitzer5, Zachariah DeFilipp5, Jennifer S Temel5, Areej El-Jawahri5.   

Abstract

Chronic graft-versus-host disease (GVHD) is one of most common complications following allogeneic hematopoietic cell transplantation (HCT) and the most significant contributor to morbidity and nonrelapse mortality. The physical burdens and psychosocial difficulties of these patients have not been described systematically. An exploration into the rates and correlates of mood and quality of life (QOL) in patients with chronic GVHD is necessary to develop a clinically relevant, evidence-based intervention to promote well-being. From July 2015 to July 2017, adult allogeneic HCT survivors with established moderate to severe chronic GVHD (N = 52) enrolled in a prospective, longitudinal study at a tertiary academic center. We examined the rates and correlates of depression and anxiety symptoms (Hospital Anxiety and Depression Scale) and explored whether constructs including coping strategies (Coping Inventory for Stressful Situations), symptom burden (Lee Symptom Assessment Scale), physical functioning (Human Activity Profile), and perceived social support (Medical Outcomes Study Social Support Survey) predicted QOL trajectory over time (Functional Assessment of Cancer Therapy-Bone Marrow Transplant) at the baseline, 3-month, and 6-month follow-up. Analyses adjusted for age, sex, chronic GVHD severity, and time since chronic GVHD diagnosis. At the baseline, 3-month, and 6-month follow-up, 32.7%, 31.1%, and 37.8% of patients reported clinically significant depression symptoms, and 30.8%, 20.0%, and 36.4% reported clinically elevated anxiety symptoms, respectively. Adjusting for covariates, greater use of negative emotion-oriented coping (β = 0.20, P = .002), less use of task-oriented coping (β = -0.10, P = .021), worse physical functioning (β = -0.07, P = .004), and higher symptom burden (β = 0.07, P = .002) were independently associated with depression symptoms at baseline. Greater use of negative emotion-oriented coping (β = 0.28, P < .001) and worse physical functioning (β = -0.05, P = .034) were independently associated with anxiety at baseline. Patients who used more negative emotion-oriented coping (β = -0.58, P = .035), had less task-oriented (β = 0.40, P = .028) and social diversion-oriented coping (β = 0.35, P = .039), and had higher symptom burden (β = -0.30, P = .001), worse physical functioning (β = 0.32, P < .001), and lower perceived social support (β = 6.47, P = .003) at baseline reported poorer QOL over time. The unmet physical and psychosocial needs of patients with chronic GVHD are substantial and warrant investigation into evidence-based interventions that may improve QOL and mood by targeting modifiable psychosocial constructs identified in this study.
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Chronic GVHD; Coping; Depression; Quality of life

Year:  2019        PMID: 31260800     DOI: 10.1016/j.bbmt.2019.06.024

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  8 in total

1.  Psychosocial and financial issues after hematopoietic cell transplantation.

Authors:  David Buchbinder; Nandita Khera
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  What else do I need to worry about when treating graft-versus-host disease?

Authors:  Areej El-Jawahri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

3.  Coping strategies in patients with acute myeloid leukemia.

Authors:  Hermioni L Amonoo; Monica H Bodd; Matthew J Reynolds; Ashley M Nelson; Richard Newcomb; Patrick Connor Johnson; Tejaswini M Dhawale; Rachel Plotke; Lauren Heuer; Sabah Gillani; Daniel Yang; Emma C Deary; Elizabeth Daskalakis; Lauren Goldschen; Andrew Brunner; Amir T Fathi; Thomas W LeBlanc; Areej El-Jawahri
Journal:  Blood Adv       Date:  2022-04-12

Review 4.  Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.

Authors:  Dylan J Martini; Yi-Bin Chen; Zachariah DeFilipp
Journal:  Oncologist       Date:  2022-08-05       Impact factor: 5.837

Review 5.  Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective-A Literature Review.

Authors:  Freya Wenzel; Anne Pralong; Udo Holtick; Christoph Scheid; Marco Herling; Steffen T Simon
Journal:  Cancers (Basel)       Date:  2021-05-30       Impact factor: 6.639

6.  Depression following graft-versus-host disease in a patient with acute lymphoblastic leukaemia: A case report.

Authors:  Konstantinos Tsamakis; Christoph Mueller; Panagiotis Tsirigotis; Dimitrios Tsiptsios; Charalampos Tsamakis; Emmanouil Charakopoulos; Chistophis Charalampous; Demetrios A Spandidos; Athanasios Douzenis; Charalabos Papageorgiou; Ioannis Liappas; Emmanouil Rizos
Journal:  Mol Clin Oncol       Date:  2019-12-19

Review 7.  Steroid-refractory chronic graft-versus-host disease: treatment options and patient management.

Authors:  Daniel Wolff; Giancarlo Fatobene; Vanderson Rocha; Nicolaus Kröger; Mary E Flowers
Journal:  Bone Marrow Transplant       Date:  2021-07-03       Impact factor: 5.483

8.  Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.

Authors:  Zachariah DeFilipp; Amin M Alousi; Joseph A Pidala; Paul A Carpenter; Lynn E Onstad; Sally Arai; Mukta Arora; Corey S Cutler; Mary E D Flowers; Carrie L Kitko; George L Chen; Stephanie J Lee; Betty K Hamilton
Journal:  Blood Adv       Date:  2021-10-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.